7/28/2019 Ipratropium_salbutamol

1/1

Ipratropium salbutamol (Duavent) nebule, 1 nebule PRN for dyspnea

DRUGNAME

MECHANISM OF ACTION INDICATION ADVERSE EFFECT OVERDOSAGE CONTRAINDICATION

NURSINGRESPONSIBILITY

IpratropiumSalbutamol

Duavent500 mcg /2.5 mg per2.5 ml

pulmoneb

Solunon fornebulizano

n

FORMULA

TION:Each 2.5mL

pulmonebcontains:Ipratropium

bromide(anhydrous) 500 mcgSalbutamol(as sulfate)

2.5 mg

Anticholinergic / Beta,-agonistIpratropium bromide

Antiasthmatic & COPD PreparationsPharmacology: Ipratropium bromide:Ipratropium bromide is a quaternaryammonium compound with

anticholinergic (parasympatholytic)properties. Similar to atropine, it is a

nonselective competitive antagonistof muscarinic receptors present in

airways and other organs. Ipratropiumbromide relaxes smooth muscles of

bronchi and bronchioles by blocking

acetylcholine-induced stimulation ofguanyl cyclase, thus reducingformation of cyclic guanosinemonophosphate (cGMP), a mediatorof bronchoconstriction.

Salbutamol: Salbutamol stimulatesadenyl cyclase, the enzyme whichcatalyzes the formation of cyclic-3',5'-adenosine monophosphate (cAMP)from adenosine triphosphate (ATP).

The cAMP thus formed mediates thecellular response eg, bronchialsmooth muscle relaxation.Invitro and in vivo pharmacologicstudies have demonstrated thatsalbutamol has a preferential effect on-adrenergic receptors that areespecially found in respiratory tractcompared with isoproterenol.

Managementofreversiblebro

nchospasm associated withobstructiveairway

diseases (eg,bronchial

asthma).For patients

withchronic obstru

ctive

pulmonarydisease (COPD) on aregularinhaled

bronchodilatorwho continueto haveevidenceofbronchospasm and who

require asecondbronchodilator.

Gastrointestinal:Nausea.Respiratory: Bronchitis,

dyspnea, coughing,pneumonia,bronchospasm,pharyngitis, sinusitis,

rhinitis.Additional adverse

reactions, reported in